Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 28

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 28
---
 $m of cash collateral pledged to counterparties. The total fair value of Interest-bearing loans and borrowings as at 30 June 2025, which have a carrying value of $m in the Condensed consolidated statement of financial position, was $m.

Table 22: Contingent consideration

| ​                                       | ​ |        ​ | ​ |     ​ | ​ |     ​ | ​ |     ​ |
| ​                                       | ​ |     2025 |   |       |   |       | ​ |  2024 |
| ​                                       | ​ | Diabetes | ​ |     ​ | ​ |     ​ | ​ |     ​ |
| ​                                       |   | alliance |   | Other |   | Total |   | Total |
| ​                                       | ​ |       $m | ​ |    $m | ​ |    $m | ​ |    $m |
| At 1 January                            |   |    1,309 | ​ |   442 | ​ | 1,751 | ​ | 2,137 |
| Additions through business combinations | ​ |        - | ​ |     - | ​ |     - | ​ |   198 |
| Settlements                             |   |     -518 | ​ |  -111 | ​ |  -629 | ​ |  -474 |
| Revaluations                            | ​ |      -30 | ​ |     - | ​ |   -30 | ​ |   251 |
| Discount unwind                         |   |       21 | ​ |    11 | ​ |    32 | ​ |    57 |
| At 30 June                              |   |      782 | ​ |   342 | ​ | 1,124 | ​ | 2,169 |

Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues.

The contingent consideration balance relating to BMS’s share of the global diabetes alliance of$ 782m (31 December 2024:$ 1,309m) would increase/decrease by$ 78m with an increase/decrease in sales of10%, as compared with the current estimates.

Note 5: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights,